Target intelligence / Profile preview

T-cell surface glycoprotein CD3 epsilon chain (CD3E) (CD3E)

Target
CD3E
Molecular classification
Receptor, CD antigen, Other
01

Overview

The T-cell surface glycoprotein CD3 epsilon chain (CD3E) is a critical transmembrane protein that functions as a key subunit of the T-cell receptor (TCR)-CD3 complex on the surface of T-lymphocytes [1, 10]. It is essential for the adaptive immune response, as it facilitates the transduction of signals from the TCR to the cytoplasm upon antigen recognition through its immunoreceptor tyrosine-based activation motifs (ITAMs) [1, 8]. CD3E is also vital for the assembly and stable expression of the TCR complex and plays a non-redundant role in T-cell development within the thymus [1, 11]. Clinically, CD3E is a prominent therapeutic target for both immunosuppression and oncology; monoclonal antibodies like muromonab-CD3 and teplizumab modulate T-cell activity to treat transplant rejection and autoimmune diseases, while bispecific T-cell engagers (BiTEs) like blinatumomab recruit T-cells to kill cancer cells [12, 14, 17]. However, the potent activation of T-cells via CD3E can lead to severe adverse effects, most notably cytokine release syndrome (CRS) and neurotoxicity, which require careful clinical management [15, 16, 19]. Genetic defects in CD3E lead to severe combined immunodeficiency, underscoring its indispensable role in maintaining a functional immune system [6, 12].

Other names
CD3e moleculeT3ETCRECD3 epsilon subunit of T-cell receptor complexIMD18CD antigen CD3e
02

Mechanism of action

Redirection of cytotoxic T-cells to tumor cells via bispecific antibodies; immunosuppression through T-cell depletion or TCR-CD3 complex internalization; and modulation of T-cell responses via partial agonism.

03

Biological functions

Signal transductionImmune responseCell differentiationT-cell activation
04

Disease associations

CancerInflammationInfectionOther
05

Safety considerations

Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)LymphopeniaHypogammaglobulinemiaInfusion-related reactionsInfection risk
06

Interacting drugs

Muromonab-CD3

12 more in the full profile.

07

Biomarkers

CD3 expressionT-cell countSerum IL-6 levelsSerum IFN-gamma levelsMinimal residual disease (MRD)

Beyond the preview

Go deeper on T-cell surface glycoprotein CD3 epsilon chain (CD3E) (CD3E).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell surface glycoprotein CD3 epsilon chain (CD3E) (CD3E).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call